Olive AI was a healthcare technology company that used artificial intelligence and automation to streamline hospital administration, revenue cycle management, and other healthcare workflows. The company announced it was winding down in October 2023 after selling key business units to Waystar and Humata Health, making its history an important case study in healthcare AI adoption.
At a Glance
- What it was: A healthcare automation company founded in 2012 and headquartered in Columbus, Ohio.
- Primary purpose: Automate repetitive administrative work for hospitals, health systems, and healthcare organizations.
- Key applications: Insurance eligibility checks, medical claims processing, revenue cycle management, and prior authorization.
- Major milestone: Olive reached a reported $4 billion valuation in 2021.
Healthcare News & Analysis+1
- What happened: The company announced its shutdown and asset sales on October 31, 2023.
- Why it matters: Its history illustrates the challenges of turning AI automation into reliable, financially sustainable healthcare operations.
What Was Olive AI?
Olive AI was an American healthcare technology company that developed software to automate administrative processes across hospitals and health systems. Its goal was to reduce repetitive manual work, improve operational efficiency, and help healthcare organizations manage complex workflows.
Healthcare providers deal with substantial administrative workloads. Staff members must verify insurance coverage, submit claims, manage authorizations, reconcile payments, and coordinate information across different systems.
Olive aimed to automate parts of this work using artificial intelligence, machine learning, robotic process automation, and integrations with healthcare software.
The company attracted significant investor attention during the healthcare technology boom of 2020 and 2021. Its valuation reportedly reached $4 billion in July 2021, making it one of the most prominent healthcare automation startups of that period.
However, Olive AI is no longer operating as the independent company it once was. It announced plans to wind down its remaining operations in October 2023 after selling key business units.
This distinction is essential for anyone researching Olive AI today. Historical articles may describe its former products and capabilities, but those descriptions should not be interpreted as an offer of currently available services.
What Did Olive AI Do?
Olive focused on administrative healthcare operations rather than acting primarily as a diagnostic AI system. Its software targeted repetitive processes that consume staff time and affect how healthcare organizations receive payment for services.
1. Revenue Cycle Management
Revenue cycle management, or RCM, covers the administrative and financial processes involved in getting paid for healthcare services.
These processes can begin with patient registration and insurance verification, then continue through claims submission, payment processing, and denial management.
Olive developed automation products intended to streamline parts of this workflow. The broader objective was to reduce manual processing and help providers manage administrative tasks more consistently.
For example, a hospital might need to verify insurance information before a scheduled procedure. Automation can help retrieve information, identify missing details, and route exceptions to staff.
The value depends on whether the software works reliably within the provider’s existing systems and handles exceptions correctly.
2. Insurance Eligibility Verification
Before delivering services, healthcare organizations often need to confirm a patient’s insurance coverage and benefits.
Manual verification can require staff to access payer portals, review patient details, and enter information into multiple systems.
Olive’s historical automation portfolio included eligibility-related administrative workflows. Automating these tasks could reduce repetitive data entry, although actual results depend on payer systems, data quality, and implementation.
3. Claims and Payment Processing
Healthcare claims contain information about services delivered, billing codes, providers, and insurance coverage. Errors or missing information can delay reimbursement or lead to rejected claims.
Olive pursued automation across claims and remittance processes, which form part of the healthcare revenue cycle.
In principle, automation can move information between systems, identify routine processing tasks, and help staff manage exceptions. However, it cannot guarantee that a claim will be accepted or paid.
4. Prior Authorization
Prior authorization is the process through which an insurer determines whether certain treatments, procedures, or medications require approval before coverage.
This process can involve clinical documentation, payer requirements, status checks, and communication between healthcare providers and insurers.
Olive’s prior authorization business was among the assets sold during its 2023 wind-down. Humata Health acquired that business unit, according to reporting on the transaction.
This part of Olive’s history is particularly relevant because prior authorization remains an operationally demanding area of healthcare administration.
5. Clinical and Operational Analytics
Olive also expanded beyond administrative automation through acquisitions. In 2021, it acquired Empiric Health, a company focused on clinical analytics and identifying unwarranted variation in healthcare delivery.
This expanded its interests into operational and clinical performance analysis.
However, analytics and administrative automation serve different purposes. An analytics system helps users interpret patterns and identify opportunities, while an automation system executes or coordinates specific tasks.
That distinction matters when evaluating healthcare AI vendors and their claims.
Why Did Olive AI Shut Down?
Olive AI announced its wind-down on October 31, 2023. It sold important business units and began closing the remaining company rather than continuing as an independent healthcare automation provider.
Its closure was not the result of a single publicly established cause. Reporting and company statements point to a combination of financial pressure, execution challenges, strategic changes, and the difficulty of delivering automation across complex healthcare environments.
1. Rapid Expansion Created Execution Challenges
Olive expanded its product portfolio through acquisitions and pursued a broad vision for healthcare automation.
That strategy created opportunities to serve more administrative workflows. However, combining different products, teams, and customer requirements also increased operational complexity.
In a 2022 statement reported by Fierce Healthcare, CEO Sean Lane acknowledged that rapid growth and insufficient focus had strained product and engineering resources and slowed execution on key initiatives.
This is an important distinction: having multiple automation products does not necessarily mean they operate as one reliable, integrated system.
2. Healthcare Workflows Were Difficult to Automate
Hospitals operate through interconnected systems, each with its own data formats, access rules, and operational requirements.
A process that works in one organization may need significant adaptation in another. Insurance portals can change, records can contain inconsistencies, and exceptions may require human judgment.
Automation must also handle failures safely. A task that appears routine can create billing delays or administrative errors when the software misinterprets a record or fails to complete a transaction.
These challenges are not unique to Olive. They affect healthcare automation providers generally, particularly when software must interact with legacy systems and multiple external organizations.
3. Financial Pressure Increased
Olive attracted substantial investment and achieved a reported $4 billion valuation in 2021. However, a high private-market valuation does not establish that a business has achieved sustainable profitability or positive cash flow.
By 2023, the company was selling business units and had already undergone substantial workforce reductions. Reporting on its closure described significant financial constraints and unsuccessful efforts to secure a sustainable path forward.
The broader lesson is that venture funding can finance growth, but long-term survival depends on customers receiving measurable value at a cost the provider can sustain.
4. The Business Model Needed Sustainable Results
Healthcare organizations need more than an impressive demonstration. They need software that works consistently, integrates with existing systems, and produces operational benefits that justify its cost.
Potential benefits include fewer manual steps, reduced processing time, and improved administrative consistency. Yet those benefits must be measured against implementation expenses, maintenance, exception handling, and ongoing support.
Olive’s closure highlights the difference between the potential of AI automation and the commercial reality of delivering it across large healthcare organizations. It does not establish that all healthcare automation is ineffective.
Olive AI Timeline: From Startup to Shutdown
The following timeline summarizes major events documented in industry reporting.
2012
Company founded
Olive launches in Columbus, Ohio, with a focus on automating healthcare administrative work.
2020
Funding and acquisitions accelerate
The company raises major investment and expands its revenue cycle capabilities, including through the acquisition of Verata Health.
2021
Valuation reaches $4 billion
A major funding round raises Olive’s reported valuation to approximately $4 billion. The company continues expanding its healthcare automation portfolio.
2022
Restructuring begins
Olive reduces its workforce and divests some assets as it faces execution challenges and difficult market conditions.
2023
Business units are sold
Waystar acquires the clearinghouse and patient access assets, while Humata Health acquires the prior authorization business unit. Olive announces its wind-down on October 31.
What Happened to Olive AI’s Products and Customers?
Olive did not transfer its entire former business to a single successor. Instead, key assets were sold to different companies.
Waystar Acquired Clearinghouse and Patient Access Assets
Waystar, a healthcare payments technology company, acquired certain assets of Olive’s clearinghouse and patient access businesses on October 31, 2023.
Waystar’s regulatory filing records consideration of $10 million for those assets. This figure refers to that specific asset acquisition, not Olive’s overall historical valuation or total funding.
The transaction brought certain Olive technologies and customer relationships into Waystar’s business. It should not be interpreted as Waystar acquiring the entire Olive AI company.
Official information is available through Waystar’s investor relations website.
Humata Health Acquired the Prior Authorization Business
Humata Health acquired Olive’s prior authorization business unit as part of the wind-down.
This transaction preserved a portion of Olive’s healthcare automation work under a different company.
Humata Health has continued publishing updates about its prior authorization technology. Its newsroom reported in August 2026 that R1 had entered into an agreement to acquire Humata Health. An announced agreement should not be confused with a completed acquisition unless closing has been confirmed.
Can Hospitals Still Use the Original Olive AI Platform?
The original Olive AI business wound down in October 2023, so readers should not assume that its former platform remains available as a standalone product.
Organizations that previously used Olive should confirm their current support arrangements, software ownership, data access, and migration options directly with the relevant successor or service provider.
For new buyers, the sensible approach is to evaluate currently operating vendors rather than relying on historical Olive AI product descriptions.
Is Olive AI Still Available in 2026?
The original healthcare automation company Olive AI shut down in 2023. However, the name “Olive” and similar variations are used by other products, so current search results can be confusing.
For example, Olive at olive.app now describes a technology evaluation platform that helps businesses define requirements, research vendors, compare solutions, and produce evaluation reports. Its current offering is different from the former healthcare automation business.
Another separate product, Olive at oliveapp.com, describes a consumer health companion focused on nutrition, habit tracking, and wellness. It is not the former hospital automation company.
These distinctions matter when evaluating search results, reviewing product claims, or looking for a download.
| Name | Purpose | Current status or context |
|---|---|---|
| Original Olive AI | Healthcare administrative automation | Wound down in October 2023 |
| Olive at olive.app | AI-assisted technology vendor evaluation | Current platform with published pricing |
| Olive at oliveapp.com | Consumer health and wellness companion | Separate product with its own website |
Always verify the official domain, company identity, product documentation, and terms before signing up or sharing sensitive information.
Olive AI Alternatives for Healthcare Automation
Organizations seeking similar capabilities should compare active healthcare technology providers according to the specific workflow they need to automate. No single replacement necessarily covers every function Olive once pursued.
Relevant for healthcare payment workflows, patient access, and revenue cycle operations. Waystar acquired certain Olive clearinghouse and patient access assets in 2023.
Relevant to prior authorization and medical necessity workflows. The company acquired Olive’s prior authorization business unit.
Worth evaluating for payer-provider administrative workflows. Availity acquired Olive’s utilization management business in 2023, a separate transaction from the later asset sales to Waystar and Humata Health.
Healthcare Automation Comparison
| Platform | Target user | Key strength | Pricing transparency | Core limitation to evaluate |
|---|---|---|---|---|
| Waystar | Hospitals and healthcare providers | Payments and revenue cycle workflows | Request a current vendor quote | Confirm exact modules and integration scope |
| Humata Health | Healthcare providers and payer-facing teams | Prior authorization automation | Request a current vendor quote | Validate workflow coverage and implementation needs |
| Availity | Healthcare providers and health plans | Administrative information exchange and related workflows | Varies by product and arrangement | Confirm eligibility for the required service |
This comparison is based on the companies’ documented areas of activity and Olive’s historical asset transactions. It is not a performance ranking or a claim that every former Olive feature has a direct replacement.
Lessons Healthcare Organizations Can Learn From Olive AI
Olive’s history offers practical lessons for healthcare leaders evaluating AI automation projects.
1. Measure Operational Results, Not Just Automation Volume
Counting automated tasks does not prove that a system improves performance. Organizations should measure completed transactions, processing time, error rates, exception frequency, and staff effort.
For example, automating 10,000 claim checks may sound impressive. The result matters less if staff must manually correct a large proportion of them.
2. Evaluate Integration Before Deployment
Healthcare software must work with existing electronic health records, billing systems, payer portals, and internal procedures.
Before committing to a vendor, test the complete workflow. Identify what happens when a portal changes, a record is incomplete, or an automated action fails.
3. Start With a Specific, Measurable Problem
A broad promise to automate an entire hospital is difficult to evaluate. A defined use case, such as reducing manual eligibility checks, gives teams a clearer way to test value.
Run a controlled pilot, establish a baseline, and compare results against agreed targets before expanding deployment.
4. Account for the Full Cost of Ownership
AI projects involve more than subscription fees. Implementation, integration, maintenance, staff training, monitoring, and exception handling all affect total cost.
Calculate the expected financial benefit using realistic operational data. Avoid assuming that projected savings will automatically materialize.
5. Treat Healthcare Data Carefully
Healthcare automation can involve sensitive patient and insurance information. Buyers should review access controls, data retention, subcontractors, incident response, audit documentation, and contractual obligations.
Do not treat a vendor’s AI claims or general security statements as substitutes for a detailed assessment.
Frequently Asked Questions About Olive AI
1. What was Olive AI used for?
Olive AI developed healthcare automation software for administrative workflows, including revenue cycle management, claims processing, insurance eligibility, and prior authorization. Its products aimed to reduce repetitive manual work for hospitals and healthcare organizations.
2. Why did Olive AI shut down?
Olive AI wound down in October 2023 after facing financial constraints and operational challenges. Company statements and industry reporting described difficulties with execution, rapid expansion, and establishing a sustainable business. The closure cannot be attributed to one publicly established cause.
3. Who acquired Olive AI?
No single company acquired the entire Olive AI business. Waystar acquired certain clearinghouse and patient access assets, while Humata Health acquired the prior authorization business unit.
4. Is Olive AI still operating in 2026?
The original healthcare automation company wound down in October 2023. Other products use the Olive or OliveAI name, including a technology evaluation platform at olive.app and a consumer wellness app at oliveapp.com. These are separate offerings.
5. What are the alternatives to Olive AI?
Potential alternatives depend on the workflow. Waystar is relevant to revenue cycle and payment operations, Humata Health focuses on prior authorization, and Availity offers healthcare administrative technology. Buyers should verify current product capabilities, integrations, pricing, and service availability before choosing a provider.
Conclusion
Olive AI was an ambitious healthcare automation company that sought to reduce administrative burdens across hospitals and health systems. Despite reaching a reported $4 billion valuation, it wound down in 2023 after selling key business units.
Its history demonstrates why successful healthcare AI requires more than investment and technical ambition. Reliable integration, measurable operational benefits, financial discipline, and effective customer support are equally important.
For healthcare organizations exploring automation today, the practical lesson is to choose a specific problem, test measurable outcomes, and evaluate the full cost and risk of deployment. Also verify company identities carefully, because newer products share the Olive name but do not represent the original healthcare startup.
Oliver Wilson is an AI researcher and tech writer living at the intersection of human creativity and machine intelligence. At AixOrbit.com, he decodes complex neural networks, generative AI and emerging tech trends into actionable insights making sure humans stay one step ahead of the algorithms.